CM
CORT icon

Crestline Management’s Corcept Therapeutics CORT Stock Holding History

Crestline Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,774
Closed -$694K – 139
2024
Q4 		$694K Buy
13,774
+4,615
+50% +$242K 0.02% 481
2024
Q3 		$424K Buy
+9,159
New +$325K 0.02% 401

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Crestline Management's CORT Position: Q1 2025 in Review

Crestline Management sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 13,774 shares — an estimated $694K sold.

Crestline Management first reported a position in CORT in Q3 2024 and held it in 2 quarters. The position peaked at $694K in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

  • Crestline Management reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 13,774 Corcept Therapeutics shares in Q1 2025, an estimated $694K.
  • Crestline Management first reported a position in Corcept Therapeutics in Q3 2024 and held it in 2 quarters.
  • Crestline Management's Corcept Therapeutics position peaked at $694K in Q4 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.